Fig. 4: LY3039478 inhibits iCCA progression in the PDX model similarly to gemcitabine. | Cell Death & Differentiation

Fig. 4: LY3039478 inhibits iCCA progression in the PDX model similarly to gemcitabine.

From: Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis

Fig. 4

The tumor progression of masses in PDX mice that received LY3039478 was delayed compared with vehicle and gemcitabine. Extra 18 days for LY3039478 group and extra 11 days for gemcitabine group after treatment end were given. The results show a slow recovery of progression in both treatment groups compared with the control group (vehicle) (b). At the end of the experiments, the size and weight (a) of the masses were visibly smaller than the control masses. **P < 0.01, ***P < 0.001 compared with treatment with vehicle.

Back to article page